NSF Nanoscale Science and Engineering Center (NSEC), The Ohio State University, Columbus, USA.
J Control Release. 2013 Dec 28;172(3):690-8. doi: 10.1016/j.jconrel.2013.09.027. Epub 2013 Oct 8.
Many cationic lipids have been developed for lipid-based nanoparticles (LNPs) for delivery of siRNA and microRNA (miRNA). However, less attention has been paid to "helper lipids". Here, we investigated several "helper lipids" and examined their effects on the physicochemical properties such as particle size and zeta potential, as well as cellular uptake and transfection efficiency. We found that inclusion of oleic acid (OA), an unsaturated fatty acid, into the LNP formulation significantly enhanced the delivery efficacy for siRNA and miRNA. For proof-of-concept, miR-122, a liver-specific microRNA associated with many liver diseases, was used as a model agent to demonstrate the hepatic delivery efficacy both in tumor cells and in animals. Compared to Lipofectamine 2000, a commercial transfection agent, LNPs containing OA delivered microRNA-122 in a more efficient manner with a 1.8-fold increase in mature miR-122 expression and a 20% decrease in Bcl-w, a target of microRNA-122. In comparison with Invivofectamine, a commercial transfection agent specifically designed for hepatic delivery, LNPs containing OA showed comparable liver accumulation and in vivo delivery efficiency. These findings demonstrated the importance of "helper lipid" components of the LNP formulation on the cellular uptake and transfection activity of siRNA and miRNA. LNPs containing OA is a promising nanocarrier system for the delivery of RNA-based therapeutics in liver diseases.
许多阳离子脂质已被开发用于基于脂质的纳米颗粒(LNPs)以递送 siRNA 和 microRNA(miRNA)。然而,人们对“辅助脂质”的关注较少。在这里,我们研究了几种“辅助脂质”,并考察了它们对颗粒大小和 zeta 电位等理化性质以及细胞摄取和转染效率的影响。我们发现,将不饱和脂肪酸油酸(OA)纳入 LNP 配方中显著增强了 siRNA 和 miRNA 的递送效果。为了验证概念,我们选择 miR-122 作为模型药物,miR-122 是一种与许多肝脏疾病相关的肝脏特异性 microRNA,用于在肿瘤细胞和动物中证明其肝脏递送效果。与商业转染试剂 Lipofectamine 2000 相比,含有 OA 的 LNPs 以更高的效率递送 microRNA-122,使成熟的 miR-122 表达增加 1.8 倍,miR-122 的靶标 Bcl-w 减少 20%。与专门用于肝脏递送的商业转染试剂 Invivofectamine 相比,含有 OA 的 LNPs 显示出相当的肝脏积累和体内递送效率。这些发现表明 LNP 配方中“辅助脂质”成分对 siRNA 和 miRNA 的细胞摄取和转染活性的重要性。含有 OA 的 LNPs 是一种有前途的纳米载体系统,可用于肝脏疾病的 RNA 治疗药物的递送。